3-ethyl-azepan-2-one | 4751-71-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 内酰胺类
• 英文名称: 3-ethyl-azepan-2-one
• 英文别名: 3-ethyl-hexahydro-azepin-2-one；3-Aethyl-hexahydro-azepin-2-on；Ethylcaprolactam；3-ethylazepan-2-one
• CAS: 4751-71-7
• 化学式: C₈H₁₅NO
• 分子量: 141.213
• InChiKey: XJKHICJWKIWYGC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  10
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.88
• 拓扑面积：
  29.1
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  3-ethyl-azepan-2-one 在 三乙胺 、 lithium diisopropyl amide 作用下， 以 苯 为溶剂， 生成 hexahydro-3,3-diethyl-2H-azepin-2-one
  参考文献：
  名称：

  Synthesis and Anticonvulsant Activities of 3,3-Dialkyl- and 3-Alkyl-3-benzyl-2-piperidinones (δ-Valerolactams) and Hexahydro-2H-azepin-2-ones (ε-Caprolactams)

  摘要：

  A series of 3-substituted 2-piperidinone (delta-valerolactam) and hexahydro-2H-azepin-2-one (epsilon-caprolactam) derivatives were prepared and evaluated as anticonvulsants in mice. In the 2-piperidinone series, 3,3-diethyl compound 7b is the most effective anticonvulsant against pentylenetetrazole-induced seizures (ED(50), 37 mg/kg; PI (TD50/ED(50)), 4.46), and 3-benzyl compound 4c (ED(50), 41 mg/kg; PI, 7.05) is the most effective anticonvulsant against-seizures induced by maximal electroshock. By contrast, none of the epsilon-caprolactams tested had anticonvulsant effects below doses causing rotorod toxicity. log P values were correlated with neurotoxicity and [S-35]TBPS displacement, but not with anticonvulsant activity. Electrophysiological evaluations of selected compounds from each series indicated that both the delta-valerolactams and epsilon-caprolactams potentiated GABA-mediated chloride currents in rat-hippocampal neurons.

  DOI：

  10.1021/jm960561u
• 作为产物：
  描述：

  2-ethyl-cyclohexanone oxime 在 硫酸 作用下， 生成 3-ethyl-azepan-2-one
  参考文献：
  名称：

  2-Iminohomopiperidinium Salts as Selective Inhibitors of Inducible Nitric Oxide Synthase (iNOS)

  摘要：

  An attractive approach to the treatment of inflammatory conditions such as osteo-and rheumatoid arthritis, inflammatory bowel disease, and sepsis is through the selective inhibition of human inducible nitric oxide synthase (hiNOS) since localized excess nitric oxide (NO) release has been implicated in the pathology of these diseases. A series of monosubstituted iminohomopiperidinium salts possessing lipophilic functionality at ring positions 3, 5, 6, and 7 has been synthesized, and series members have demonstrated the ability to inhibit the hiNOS isoform with an IC50 as low as 160 nM (7). Compounds were found that selectively inhibit hiNOS over the human endothelial constitutive enzyme (heNOS) with a heNOS/hiNOS IC50 ratio in excess of 100 and as high as 314 (9). Potencies for inhibition of hiNOS and the human neuronal constitutive enzyme (hnNOS) are comparable. Substitution in the 3 and 7 positions provides compounds that exhibit the greatest degree of selectivity for hiNOS and hnNOS over heNOS. Submicromolar potencies for 6 and 7 in a mouse RAW cell assay demonstrated the ability of these compounds to inhibit iNOS in a cellular environment. These latter compounds were also found to be orally bioavailable and efficacious due to their ability to inhibit the increase in plasma nitrite/nitrate levels in a rat LPS model.

  DOI：

  10.1021/jm9704715

文献信息

• Directing Group in Decarboxylative Cross-Coupling: Copper-Catalyzed Site-Selective C–N Bond Formation from Nonactivated Aliphatic Carboxylic Acids
  作者：Zhao-Jing Liu、Xi Lu、Guan Wang、Lei Li、Wei-Tao Jiang、Yu-Dong Wang、Bin Xiao、Yao Fu

  DOI：10.1021/jacs.6b05788

  日期：2016.8.3

  Copper-catalyzed directed decarboxylative amination of nonactivated aliphatic carboxylic acids is described. This intramolecular C-N bond formation reaction provides efficient access to the synthesis of pyrrolidine and piperidine derivatives as well as the modification of complex natural products. Moreover, this reaction presents excellent site-selectivity in the C-N bond formation step through the

  描述了铜催化的非活化脂肪族羧酸的定向脱羧胺化。这种分子内 CN 键形成反应为合成吡咯烷和哌啶衍生物以及复杂天然产物的修饰提供了有效途径。此外，该反应通过使用导向基团在 CN 键形成步骤中表现出优异的位点选择性。我们的工作可以被认为是朝着可控自由基脱羧碳-杂原子交叉偶联迈出的一大步。
• Heterobicyclic and tricyclic nitric oxide synthase inhibitors
  申请人：——

  公开号：US20010044539A1

  公开（公告）日：2001-11-22

  The current invention discloses useful bicyclic and tricyclic amidino derivative compounds, pharmaceutical compositions containing these novel compounds, and to their use as nitric oxide synthase inhibitors.

  当前的发明揭示了有用的双环和三环氨基甲酰衍生物化合物，含有这些新化合物的药物组合物，以及它们作为一氧化氮合酶抑制剂的用途。
• [EN] PROCESS FOR THE SYNTHESIS OF N-SUBSTITUTED LACTAMS AND AMIDES<br/>[FR] PROCÉDÉ DE SYNTHÈSE D'AMIDES ET DE LACTAMES N-SUBSTITUÉS
  申请人：ADVANSIX RESINS & CHEMICALS LLC

  公开号：WO2021119004A1

  公开（公告）日：2021-06-17

  A process for the synthesis of N-alkylated lactams via reductive alkylation. The process of the present disclosure may be conducted by the addition of an aldehyde to a lactam in the presence of a catalyst under a reducing atmosphere.

  一种通过还原烷基化反应合成N-烷基化内酰胺的方法。本公开的方法可以通过在还原气氛下，在催化剂的存在下将醛加入内酰胺中来进行。
• Pyrrolo[1,2-b][1,2,4]oxadiazine diones useful as nitric oxide synthase inhibitors
  申请人：——

  公开号：US20040019019A1

  公开（公告）日：2004-01-29

  The current invention discloses useful bicyclic and tricyclic amidino derivative compounds, pharmaceutical compositions containing these novel compounds, and to their use as nitric oxide synthase inhibitors.

  当前发明揭示了有用的双环和三环氨基甲酰衍生物化合物，含有这些新化合物的制药组合物，并且它们作为一氧化氮合酶抑制剂的用途。
• DIPEPTIDE ANALOGS AS COAGULATION FACTOR INHIBITORS
  申请人：Pinto Donald J.P.

  公开号：US20100173899A1

  公开（公告）日：2010-07-08

  Disclosed are novel dipeptide analogs compounds of Formula (I), (II) or (III): or a stereoisomer, a tautomer, a pharmaceutically acceptable salt, a solvate, or a prodrug thereof, which are inhibitors of factor XIa and/or plasma kallikrein, compositions containing them, and methods of using them, for example, for the treatment or prophylaxis of thrombotic diseases.

  本发明涉及化合物的新型二肽类似物，其化学式为(I)、(II)或(III)：或其立体异构体、互变异构体、药学上可接受的盐、溶剂化物或前药，其为血凝酶因子XIa和/或血浆卡利肌酶的抑制剂，含有它们的组合物以及使用它们的方法，例如用于治疗或预防血栓性疾病。